Table 1.
KI efficiency in pig parthenogenetic embryos treated with small molecules
| Treatment | Injected embryos | 2-cell (%) | Blastocysts (%) | KI rate (%) |
|---|---|---|---|---|
| Control | 466 | 77.52 ± 3.06ab | 48.87 ± 4.84c | 11.81 ± 1.84a |
|
Irinotecan (5 µM) |
460 | 81.12 ± 2.46b | 46.97 ± 4.62c | 23.61 ± 2.50b |
|
Docetaxel (0.5 µM) |
460 | 62.97 ± 3.36ab | 19.14 ± 3.46b | 23.61 ± 3.67b |
|
Mitomycin C (0.5 µM) |
447 | 70.81 ± 4.98ab | 18.31 ± 4.66b | 22.22 ± 2.78b |
|
Nocodazole (0.1 µM) |
302 | 75.53 ± 3.48ab | 42.00 ± 4.59c | 30.56 ± 1.39C |
| Irinotecan + Mitomycin C | 120 | 70.83 ± 5.83ab | 5.00 ± 1.67a | 25.00 ± 25.00abc |
| Docetaxel + Nocodazole | 184 | 56.14 ± 8.07a | 16.14 ± 2.66b | 30.56 ± 2.78C |
KI rates are ratios of blastocysts with HindIII-cut alleles to all blastocysts
a,b,cDifferent letters indicate statistically significant differences between groups (mean ± SEM, P < 0.05)